Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient

被引:0
|
作者
Giger-Pabst, Urs [1 ]
Solass, Wiebke [3 ]
Buerkle, Bernd [2 ]
Reymond, Marc-Andre [1 ]
Tempfer, Clemens B. [2 ]
机构
[1] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
关键词
Ovarian cancer; quality of life; antineoplastic agents; adverse effects; intraperitoneal chemotherapy; peritoneal carcinomatosis; octogenarian; high pressure; QUALITY-OF-LIFE; PERITONEAL CARCINOMATOSIS; FEASIBILITY; CISPLATIN; WOMEN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin is a form of intra-abdominal chemotherapy which can be applied repeatedly and potentially prevents from the systemic side-effects of chemotherapy. Case Report: We present the case of an 84-year-old woman with laparoscopically and histologically confirmed ovarian cancer who refused to undergo systemic chemotherapy. She was treated with eight courses q 28-104 days of low-dose PIPAC with cisplatin at 7.5 mg/m(2) and doxorubicin at 1.5 mg/m(2) at 12 mmHg and 37 degrees C for 30 min. Objective tumor response was noted, defined as tumor regression on histology, and stable disease noted by peritoneal carcinomatosis index on repeated video-laparoscopy and abdominal computed tomographic scan. The treatment was well-tolerated with no Common Terminology Criteria for Adverse Events (CTCAE) CTCAE >2. With a follow-up of 15 months, the patient is alive and clinically stable. The quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 demonstrated improvement over 5-6 months (global physical score, global health score, global quality of live) without cumulative increase of gastrointestinal toxicity. Conclusion: Low-dose PIPAC is a new form of intra peritoneal chemotherapy which may be applied repeatedly in octogenarian patients. PIPAC may be an alternative and well-tolerated treatment for selected octogenarian patients with ovarian cancer limited to the abdomen who cannot be treated with systemic chemotherapy.
引用
收藏
页码:2309 / 2314
页数:6
相关论文
共 50 条
  • [21] ASO Author Reflections: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Platinum-Resistance Ovarian Cancer Patients
    Giuseppe Vizzielli
    Maria Teresa Giudice
    Anna Fagotti
    Giovanni Scambia
    Annals of Surgical Oncology, 2024, 31 : 1217 - 1218
  • [22] ASO Author Reflections: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Platinum-Resistance Ovarian Cancer Patients
    Vizzielli, Giuseppe
    Giudice, Maria Teresa
    Fagotti, Anna
    Scambia, Giovanni
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1468 - 1476
  • [23] Is Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) Effective in Ovarian Cancer With Peritoneal Metastasis?
    Mohammad, Amad
    Hor, Mosab
    Baradeiya, Ahmed M.
    Qasim, Hodan
    Nasr, Mohamed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [24] Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Leen Van de Sande
    Wouter Willaert
    Sarah Cosyns
    Kaat De Clercq
    Molood Shariati
    Katrien Remaut
    Wim Ceelen
    BMC Cancer, 19
  • [25] Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Van de Sande, Leen
    Willaert, Wouter
    Cosyns, Sarah
    De Clercq, Kaat
    Shariati, Molood
    Remaut, Katrien
    Ceelen, Wim
    BMC CANCER, 2019, 19 (1)
  • [26] Pressurized Intraperitoneal Aerosol Chemotherapy with Low-Dose Cisplatin and Doxorubicin (PIPAC C/D) in Patients with Gastric Cancer and Peritoneal Metastasis: a Phase-II trial (PIPAC-GA1)
    Struller, F.
    Solass, W.
    Horvath, P.
    Weinreich, F.
    Strumberg, D.
    Koenigsrainer, A.
    Reymond, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 63 - 63
  • [27] SINGLE CELL TRANSCRIPTOMIC ANALYSIS OF A LOW GRADE SEROUS OVARIAN CANCER PATIENT TREATED WITH PRESSURIZED INTRAPERITONEAL AEROSOLIZED CHEMOTHERAPY (PIPAC)
    Dellinger, Thanh
    Bishara, Isaac
    Cosgrove, Patrick
    Majumdar, Sumana
    Kohut, Adrian
    Tinsley, Raechelle
    Eng, Melissa
    Frankel, Paul
    Chang, Sue
    Solass, Wiebke
    Cristea, Mihaela
    Raoof, Mustafa
    Bild, Andrea
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A189 - A190
  • [28] Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Graversen, Martin
    Detlefsen, Sonke
    Bjerregaard, Jon Kroll
    Pfeiffer, Per
    Mortensen, Michael Bau
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (05) : 309 - 314
  • [29] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer
    Alyami, Mohammad
    Bonnot, Pierre-Emmanuel
    Mercier, Frederic
    Laplace, Nathalie
    Villeneuve, Laurent
    Passot, Guillaume
    Bakrin, Naoual
    Kepenekian, Vahan
    Glehen, Olivier
    EJSO, 2021, 47 (01): : 123 - 127
  • [30] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer
    Horvath, Philipp
    Beckert, Stefan
    Struller, Florian
    Koenigsrainer, Alfred
    Reymond, Marc Andre
    CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (07) : 635 - 640